Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Problems associated with radioimmunodetection and possibilities for future solutions.

S E Halpern, R O Dillman

    Journal of Biological Response Modifiers
    |June 1, 1987
    PubMed
    Summary

    The ideal molecule for radioimmunodetection and therapy will be a small, altered human fragment targeting cell surface antigens. This molecule will be engineered for enhanced tumor targeting and reduced immunogenicity, improving diagnostic and therapeutic outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial.

    Journal of biomedicine & biotechnology·2011
    Same author

    Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.

    Cancer immunology, immunotherapy : CII·2010
    Same author

    Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.

    Clinical and experimental medicine·2006
    Same author

    Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

    Annals of oncology : official journal of the European Society for Medical Oncology·2004
    Same author

    How can we improve survival rate for patients with non-small-cell lung cancer?

    Clinical lung cancer·2004
    Same author

    Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.

    Journal of immunotherapy (Hagerstown, Md. : 1997)·2003

    Area of Science:

    • Biomedical engineering
    • Radiopharmaceutical chemistry
    • Oncology

    Background:

    • Current radioimmunodetection and radioimmunotherapy face challenges with intact antibodies, including immunogenicity and suboptimal pharmacokinetics.
    • The need for improved targeting agents with better tumor penetration and retention is critical for effective cancer treatment.

    Purpose of the Study:

    • To define the characteristics of an optimized molecule for future radioimmunodetection, radioimmunotherapy, and drug delivery.
    • To propose strategies for enhancing tumor targeting and minimizing adverse effects.

    Main Methods:

    • Conceptualization of an "ideal" molecule based on desired properties such as size, origin, labeling, and targeting specificity.
    • Discussion of potential modifications to enhance efficacy, including altered fragments, humanization, and bifunctional chelation.

    Related Experiment Videos

  • Exploration of novel administration strategies, including antigen enhancement and "priming" techniques.

    • Main Results:

    • The proposed molecule is an altered, small (approx. 60,000 MW) human or modified murine fragment designed for vascular retention and renal clearance.
    • It targets non-circulating cell surface antigens, potentially in combination with other monoclonal antibodies (MoAbs).
    • Novel strategies involve "prepping" patients with antigen-enhancing substances or using MoAbs that recruit immune cells for tumor-specific delivery.

    Conclusions:

    • The future of radioimmunodetection and therapy lies in engineered molecular fragments with tailored properties for superior targeting and efficacy.
    • These advanced agents, combined with innovative patient preparation and delivery systems, promise to revolutionize cancer diagnostics and treatment.